How we describe inequality is significant because it impacts our view of who causes it and how society should address it. Photo via Getty Images

Look closely at any news article about inequality and you will quickly notice that there is more than one way to describe what is happening.

For example:

“In 2022, men earned $1.18 for every dollar women earned.”

“In 2022, women earned 82 cents for every dollar men earned.”

“In 2022, the gender wage gap was 18 cents per dollar.”

When pointing out differences in access to resources and opportunities among groups of people, we tend to use three types of language:

  1. Advantaged — Describes an issue in terms of advantages the more dominant group enjoys.
  2. Disadvantaged — Describes an issue in terms of disadvantages the less dominant group experiences.
  3. Neutrality — Stays general enough to avoid direct comparisons between groups of people.

The difference between these three lenses, referred to as “frames” in academic literature, may be subtle. We may miss it completely when skimming a news article or listening to a friend share an opinion. But frames are more significant than we may realize.

“Frames of inequality matter because they shape our view of what is wrong and what should be fixed,” says Rice Business Professor Sora Jun.

Jun led a research team that conducted multiple studies to understand which of the three frames people typically use to describe social and economic inequality. In total, they analyzed more than 19,000 mainstream media articles and surveyed more than 600 U.S.-based participants.

In Chronic frames of social inequality: How mainstream media frame race, gender, and wealth inequality, the team published two major findings.

First, people tend to describe gender and racial inequality using the language of disadvantage. For example, “The data showed that officers pulled over Black drivers at a rate far out of proportion to their share of the driving-age population.”

Jun’s team encountered the same rhetorical tendency with gender inequality. In most cases, people describe instances of gender inequality (e.g., the gender pay gap) in terms of a disadvantage for women. We are far more likely to use the statement “Women earned 82 cents for every dollar men earned” than “Men earned $1.18 cents for every dollar women earned.”

"We expected that people would use the disadvantage framework to describe racial and gender inequalities, and it turned out to be true,” says Jun. “We think that the reason for this stems from how legitimate we perceive different hierarchies to be.” Because demographic categories like gender and race are unrelated to talent or effort, most people find it unfair that resources are distributed unevenly along these lines.

On the other hand, Jun expected people to describe wealth inequality in terms of advantage rather than disadvantage. The public typically considers this form of inequality to be more fair than racial or gender inequality. “In the U.S., there is still a widespread belief in economic mobility — that if you work hard enough, you can change the socioeconomic group you are in,” she says.

But in their second major finding, she and fellow researchers discovered that the most common frame used to describe wealth inequality was no frame at all. We find this neutrality in statements like “Disparities in education, health care and social services remain stark.”

Jun is not sure why people take a neutral approach more frequently when describing wealth inequality (speaking specifically of economic classes outside of gender and race). She suspects it has something to do with the fact that we view wealth as a fluid and continuous spectrum.

The merits of the three frames are up for debate. Using the frame of disadvantage might seem to portray issues more sympathetically, but some scholars point to potential downsides. The language of disadvantage installs the dominant group as the measuring stick for everyone else. It may also put the onus of change on the disadvantaged group while making the problem seem less relevant to the dominant group.

“When we speak about the gender gap in terms of disadvantage, and helping women earn more compared to men, we automatically assume that men are making the correct amount,” says Jun. “But maybe we should be looking at both sides of the equation.”

On the other hand, Jun cautions against using a one-size-fits-all approach to describing inequality. “We have to be careful not to jump to an easy conclusion, because the causes of inequality are so vast,” she says.

For example, men tend to interrupt conversations in team meetings at higher rates than women. “Should we frame this behavior in terms of advantage or disadvantage, which naturally leads us to prompt men to interrupt less and women to interrupt more?” asks Jun. “We really don’t know until we understand the ideal number of interruptions and why this deviation is happening. Ultimately, how we talk about inequality depends on what we want to accomplish. I hope that through this research, people will think more carefully about how they describe inequality so that they capture the full story before they act.”

------

This article originally ran on Rice Business Wisdom and was based on research from Sora Jun, Rosalind M. Chow, A. Maurits van der Veen and Erik Bleich.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”